Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma
Article 2022 en
Authors
RS
Roberta Sanfilippo
RH
Richard L. Hayward
JM
Jammbe Musoro
Abstract
1 min read
This nonrandomized phase 2 clinical trial met its primary end point, with 21 of 38 patients (55%) being progression free at 12 weeks. These results suggest important activity of cabazitaxel in patients with metastatic or inoperable locally advanced DDLPS. The drug is worth being further studied in these tumors in a phase 3 setting.
Andrew J. Wagner, Silvia Stacchiotti, C. Debruyne, Abdulazeez Salawu, Jean Yves Blay, Fernando Augusto Batista Campos, Hiroaki Hiraga, Antoine Italiano, Akira Kawai, Ganessan Kichenadasse, Yoshihiro Nishida, Seth M. Pollack, Zhe Qu, Evinaa Sellaiah, Ilona Tala, Gabriel Tinoco, Jonathan C. Trent, Karina Costa Maia Vianna, Kan Yonemori, William D. Tap
Roberta Sanfilippo, Nadia Hindi, Josefina Cruz Jurado, Jean Yves Blay, Antonio López–Pousa, Antoîne Italiano, Rosa Álvarez, Antonio Gutiérrez, Inmaculada Rincon-Pérez, Claudia Sangalli, Jose Luis Pérez Aguiar, Jesús Romero, Carlo Morosi, Marie‐Pierre Sunyach, Chiara Fabbroni, Cleofé Romagosa, Dominique Ranchère‐Vince, Angelo Paolo Dei Tos, Paolo G. Casali, Javier Martín‐Broto, Alessandro Gronchi
Dejka M. Araujo, Mihaela Druta, Mark Agulnik, Sandra P. D’Angelo, Jean Yves Blay, Sandra J. Strauss, Claudia Valverde, Albiruni Ryan Abdul Razak, Erin Van Winkle, Trupti Trivedi, Swethajit Biswas, Dennis Williams, Elliot Norry
Michael S. Hofman, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M. Joshua, David A. Pattison, Jeffrey C. Goh, Ian Kirkwood, Thean Hsiang Tan, Roslyn J. Francis, Siobhan Ng, Natalie Rutherford, Craig Gedye, Andrew M. Scott, Sze-Ting Lee, Andrew Weickhardt, Shakher Ramdave, Edmond M. Kwan, Arun Azad, W A Macdonald, Andrew D. Redfern, Alison Y. Zhang, ,
Discussion(0)
No comments yet. Be the first to comment.